adverse Obagi Skin Lightening Complex Generic Name: hydroquinone Dosage Form: topical lotion Side Effects Dosage Professional Pregnancy Reviews More Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. Obagi Skin Lightening Complex (Hydroquinone USP, 4%) Skin Bleaching Cream Rx Only FOR EXTERNAL USE ONLY Each gram of Skin Lightening Complex contains: Active ingredient: Hydroquinone USP, 4% (40 mg/g) Inactive ingredients: water, glycerin, cetyl alcohol, PPG-2 myristyl ether propionate, sodium lauryl sulfate, TEA-salicylate, lactic acid, phenyl trimethicone, tocopheryl acetate, sodium metabisulfite, ascorbic acid, methylparaben, disodium EDTA, propylparaben, saponins, BHT Slideshow Men's Health Month And Movember: Raising The Profile Of Men's Health One Stache At A Time Description: Hydroquinone is 1,4-benzenediol. The drug is freely soluble in water and in alcohol. Chemically, hydroquinone is designated as p-dihydroxybenzene; the empirical formula is C 6 H 6 O 2 ; the molecular weight is 110.11 g/mol. The chemical structure is in the diagram to the right. Clinical Pharmacology: Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (DOPA) and suppression of other melanocyte metabolic processes. Exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas, which may be prevented by the use of sunblocking agents or sunscreen agents. Indications and Usage: For the gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. Contraindications: People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established. Dosage and Administration: A thin application should be applied once or twice daily or as directed by a physician. If no improvement is seen after three (3) months of treatment, use of this product should be discontinued. Sun exposure should be limited by using a sunscreen agent, a sunblocking agent, or protective clothing to cover bleached skin when using and after using this product in order to prevent darkening from reoccurring. Warnings: Hydroquinone is a skin bleaching agent, which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this medication. Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin and check within 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, the product should be discontinued and a physician consulted. Close patient supervision is recommended. Avoid contact with the eyes, nose, mouth, and lips. In case of accidental contact, the patient should rinse thoroughly with water and contact a physician. Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity. Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. Precautions: (also see WARNINGS ) Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment. Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated. Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother. Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established. Adverse Reactions: No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur, in which case the product should be discontinued and the physician notified immediately. How Supplied: Obagi Skin Lightening Complex is available as follows: 2.0 oz. (57 g) tube NDC 62032-120-60 Store at controlled room temperature: 15 C-25 C (59 F-77 F) OBAGI MEDICAL Obagi is a registered trademark of OMP, Inc. Distributed by OMP, Inc. 2012 Obagi Medical Products, Inc. All rights reserved. Long Beach, CA 90806 Made in USA. www.obagi.com 60650612Z 09/12 PRINCIPAL DISPLAY PANEL - 57 g Carton NDC 62032-120-60 OBAGI MEDICAL ELASTI derm décolletage Chest and Neck Skin Lightening Complex Hydroquinone USP, 4% Rx Only Net wt. 2 oz. (57 g) ELASTIDERM DECOLLETAGE SKIN LIGHTENING COMPLEX CHEST AND NECK hydroquinone lotion Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:62032-120 Route of Administration TOPICAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength HYDROQUINONE (HYDROQUINONE) HYDROQUINONE 40 mg in 1 g Inactive Ingredients Ingredient Name Strength WATER GLYCERIN CETYL ALCOHOL PPG-2 MYRISTYL ETHER PROPIONATE SODIUM LAURYL SULFATE TROLAMINE SALICYLATE LACTIC ACID PHENYL TRIMETHICONE .ALPHA.-TOCOPHEROL ACETATE SODIUM METABISULFITE ASCORBIC ACID METHYLPARABEN EDETATE DISODIUM PROPYLPARABEN BUTYLATED HYDROXYTOLUENE Product Characteristics Color GRAY Score Shape Size Flavor Imprint Code Contains Packaging # Item Code Package Description 1 NDC:62032-120-60 1 TUBE in 1 CARTON 1 57 g in 1 TUBE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date Unapproved drug other 12/01/2010 Labeler - OMP, INC. (790553353) Establishment Name Address ID/FEI Operations PureTek Corporation 785961046 MANUFACTURE(62032-120), LABEL(62032-120), PACK(62032-120) Revised: 06/2014 OMP, INC. Next Pregnancy Warnings Print this page Add to My Med List More about Obagi Skin Lightening Complex (hydroquinone topical) Side Effects During Pregnancy Dosage Information 0 Reviews Add your own review/rating Drug class: topical depigmenting agents Consumer resources Professional resources Hydroquinone (AHFS Monograph) Hydroquinone Time Release Cream (FDA) Other brands: Melamin , Lustra , Melquin HP , Melpaque HP , ... +18 more Related treatment guides Dermatological Disorders FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx OTC Availability Rx and/or OTC C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Drug Class Topical depigmenting agents Related Drugs topical depigmenting agents hydroquinone topical , Melamin , Tri-Luma , Lustra Dermatological Disorders triamcinolone , clobetasol topical , betamethasone , Temovate , Diprolene , Analpram-HC , Celestone , urea topical , Valisone , Clobex , Proctofoam HC , sodium hyaluronate topical , hydroquinone topical , Olux , Diprosone , Betamethacot , salicylic acid topical , Melamin , Diprolene AF , Celestone Soluspan , Analpram E , Clobevate , More... Obagi Skin Lightening Complex Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! weakness
most shops Obagi Skin Lightening Complex earlier than
EmoticonEmoticon